Innovations for Gram-Negative Antibiotic Discovery
Funds innovative research to discover new small molecule antibiotics targeting multidrug-resistant Gram-negative bacteria, especially Klebsiella, using advanced technologies and consortium-based collaboration.
Funder: Bill and Melinda Gates Foundation
Due Dates: Letter of Inquiry due May 16, 2025 (projected); Full proposal by invitation, late June 2025 notification
Funding Amounts: Up to $5,000,000 USD total per project for up to 3 years; exploratory projects with lower budgets and shorter durations encouraged
Summary: Supports innovative, multidisciplinary research to discover new antibiotics targeting multidrug-resistant Gram-negative bacteria, focusing on Klebsiella spp.
Key Information: Applicants must agree to consortium data sharing and collaborative terms; direct-acting small molecule discovery only.
Description
This opportunity funds early-stage, multidisciplinary research to accelerate the discovery of novel antibiotics active against multidrug-resistant Gram-negative bacteria, with a primary focus on Klebsiella species and broader Enterobacteriaceae. The initiative, a collaboration among the Gates Foundation, Wellcome, and Novo Nordisk Foundation, seeks projects that employ innovative technologies—including AI-driven drug design, advanced screening, and novel target identification—to overcome current barriers in antibiotic discovery. All funded teams will join a consortium, sharing data and resources to maximize collective impact and accelerate progress toward new, resistance-breaking therapies.
